Dr. Rolando’s research addresses a common challenge in human health: the inability to diagnose diseases early enough for effective treatment, especially when symptoms are latent or non-specific. Using liquid biopsy and longitudinal studies of human health, he seeks to detect nascent diseases. Specifically, using quantitative state-of-the-art single-molecule protein-based and nucleic acid-based diagnostic tools (e.g., SIMOA, LAMP, and CRISPR), predictive machine learning models, existing clinical tools, and novel biomarkers, Justin investigates how molecular heterogeneity leads to overarching organism-level phenomena like pediatric sepsis, breast cancer, and antimicrobial resistance. When developed further, the quantitative pathophysiological research from his teams identify fingerprints of disease, paving the way for innovative diagnostics that reduced human morbidity and mortality.

See a recent article about our research efforts from the New York Times, and more under “Media Features“.